What GLP-1s Cost in 2026: Prices, Coverage, and Savings

If you've been thinking about a GLP-1 medication for weight loss but hesitated because of the price, 2026 looks different from even a year or two ago.

Some brand-name GLP-1 medications are now available through manufacturer self-pay programs at lower published cash prices than in the past. New oral options have also entered the market, giving patients more choices at different price points. Insurance coverage is still inconsistent, but new Medicare programs and manufacturer savings programs are changing what some patients pay.

Here's what GLP-1 medications cost in 2026, what's changing, and what to check before assuming you'll have to pay the full cash price.

TL;DR: Key Takeaways

• Some FDA-approved GLP-1 medications are available through manufacturer self-pay programs at substantially lower published prices than traditional cash prices.
• Wegovy tablets cost $149 per month for 1.5 mg, $199 for 4 mg, and $299 for 9 mg and 25 mg through NovoCare's self-pay program.
• Eligible new Wegovy injection patients can currently pay $199 per month for their first two monthly fills of 0.25 mg or 0.5 mg through December 31, 2026. Standard self-pay pricing is then $349 per month for the listed injection doses. Wegovy HD is $399 per month.
• Foundayo (orforglipron) has self-pay pricing starting at $149 per month for certain doses. Higher doses have different prices and eligibility requirements apply.
• The Medicare GLP-1 Bridge gives eligible Medicare Part D beneficiaries access to certain GLP-1 medications for weight management at a $50 monthly copay. The temporary program runs from July 1, 2026, through December 31, 2027.
• Compounded semaglutide is not FDA-approved. The FDA has raised concerns about dosing errors, fraudulent products, quality issues, and adverse events associated with some compounded GLP-1 products.
• Private insurance coverage varies by plan, indication, prior authorization requirements, and whether weight-loss treatment is included in the benefit.
• What you actually pay depends on the medication, dose, insurance, manufacturer programs, and whether you qualify for a particular offer.

Have questions about GLP-1 medications, cost, or coverage? Book a $39 online urgent care visit with August AI. A US-licensed clinician can review your health history and discuss whether a GLP-1 medication is appropriate for you, with same-day pharmacy pickup available across all 50 states when clinically appropriate.

The visit does not guarantee a prescription. Long-term GLP-1 weight management is typically better handled by your primary care provider or an endocrinologist who can monitor progress, adjust dosing, and coordinate other care. August online urgent care does not prescribe compounded or non-FDA-approved GLP-1 products.

How much do GLP-1 medications cost in 2026?

The short answer: some are less expensive than they used to be, but GLP-1 medications can still be costly.

Manufacturers have introduced direct-to-consumer self-pay programs with published prices for certain products and doses. New oral medications have also added more options to the market.

What you actually pay depends on the medication, dose, insurance coverage, savings programs, and whether you qualify for a particular manufacturer's offer.

Here are some currently published self-pay prices for brand-name GLP-1 medications in 2026:

These are manufacturer-published prices and offers, not necessarily the amount every patient will pay. Eligibility restrictions, dose, insurance status, savings programs, taxes, and pharmacy arrangements can affect the final cost.

Wegovy pill cost vs injection cost in 2026

The Wegovy pill cost is one of the biggest pricing changes to watch in 2026. Novo Nordisk's self-pay program lists different prices depending on the tablet dose.

Current published Wegovy tablet pricing is:

The 1.5 mg tablet is the starting dose. Wegovy tablets are increased over time, and the FDA-approved recommended maintenance dose for weight reduction in adults is 25 mg once daily. That means the $149 starting price should not be treated as the ongoing cost for everyone taking the pill.

The injection has a different pricing structure. Eligible new patients can currently pay $199 per month for their first two monthly fills of the 0.25 mg or 0.5 mg dose through December 31, 2026. Standard self-pay pricing is $349 per month for the listed Wegovy injection doses, while Wegovy HD 7.2 mg is $399 per month.

So when you're comparing Wegovy pill cost with injection cost, don't compare the $149 starting tablet price with the $349 injection price and assume those will be your long-term costs. The dose, treatment stage, and eligibility for temporary offers all matter.

For a fuller comparison of oral and injectable options, see our guide on GLP-1 pills vs injections: cost, results, and trade-offs.

Why are GLP-1 prices changing in 2026?

There isn't one reason GLP-1 prices are changing. Several developments are happening at the same time.

More competition

Wegovy and Zepbound are no longer the only major prescription options used for weight management. New oral products such as Foundayo and Wegovy tablets have added more choices, giving manufacturers another way to compete for patients who pay out of pocket.

Direct-to-consumer pharmacy programs

Novo Nordisk and Eli Lilly have introduced manufacturer-run self-pay programs that publish specific cash prices for eligible patients. These programs give patients another way to purchase certain medications outside their insurance benefit.

New oral options

Oral GLP-1 medications have added another part of the market. Foundayo and Wegovy tablets give patients options beyond weekly injections, with manufacturer-published self-pay prices that vary by dose.

Changes in coverage and access

Coverage is also changing in some settings. The Medicare GLP-1 Bridge began July 1, 2026, and provides eligible Medicare Part D beneficiaries access to certain GLP-1 medications for weight management at a $50 monthly copay. The program operates outside the normal Medicare Part D benefit and runs through December 31, 2027.

That does not mean every GLP-1 is inexpensive or covered by every insurance plan. It means some patients now have additional ways to access certain medications at a lower out-of-pocket cost.

Medicare GLP-1 coverage in 2026

Medicare access to GLP-1 medications has changed in 2026 with the launch of the temporary Medicare GLP-1 Bridge.

The Medicare GLP-1 Bridge

Starting July 1, 2026, CMS began the Medicare GLP-1 Bridge, a short-term demonstration running through December 31, 2027. Eligible Medicare Part D beneficiaries can access certain GLP-1 medications for weight management for a $50 monthly copay. The program operates outside the normal Medicare Part D payment and coverage flow. CMS explains the program and its eligibility requirements here.

The eligible products currently include Foundayo, Wegovy injections and tablets, and the KwikPen formulation of Zepbound when used to reduce excess body weight or maintain weight reduction.

Eligibility and prior authorization requirements apply. CMS currently requires beneficiaries to meet specific clinical criteria, including age, BMI, and certain health conditions, at the time GLP-1 therapy was initiated.

The $50 copay is handled outside the normal Medicare Part D payment flow. The Part D deductible does not apply, and the $50 copay does not count toward TrOOP.

Other Medicare coverage

Outside the GLP-1 Bridge, Medicare coverage depends on the medication's approved indication and the applicable Medicare benefit. Some GLP-1 medications are covered through Part D when prescribed for covered indications such as type 2 diabetes. Wegovy also has an FDA-approved indication for reducing the risk of certain cardiovascular events in adults with established cardiovascular disease and overweight or obesity.

If you're on Medicare and considering a GLP-1, check which coverage pathway applies to your prescription and whether you meet the program's eligibility requirements.

Insurance coverage for GLP-1s

Private insurance coverage still varies substantially.

Employer-sponsored plans

Coverage depends on the specific plan. Some employer plans cover GLP-1s for weight management, while others exclude weight-loss medications. Prior authorization may also be required.

Individual and marketplace plans

Coverage can vary by insurer, state, and plan. A medication being FDA-approved for weight management does not automatically mean every marketplace plan will cover it.

Prior authorization

Even when coverage exists, insurers may require prior authorization. Requirements can include specific BMI thresholds, certain health conditions, documentation of previous treatment attempts, or other criteria set by the plan.

Step therapy

Some plans require members to try other treatments before approving a GLP-1. These requirements vary by insurer and plan.

If your plan covers a GLP-1, a manufacturer savings program may reduce your out-of-pocket cost if you're eligible. For example, NovoCare currently advertises commercial-insurance savings of as little as $25 per month for eligible patients. Government beneficiaries are excluded from that particular offer.

Is compounded semaglutide safe and cheaper?

Compounded semaglutide can be less expensive than some brand-name options, which is one reason people look for it. But price alone does not tell you whether a compounded medication is appropriate for you.

Compounded semaglutide is not the same as FDA-approved Wegovy or other FDA-approved semaglutide products. Compounded drugs do not go through the FDA's premarket review for safety, effectiveness, and quality that approved drugs undergo.

The FDA has raised concerns about some compounded GLP-1 products, including:

• Dosing errors involving compounded injectable semaglutide
• Adverse events, including reports involving hospitalization
• Fraudulent products carrying false pharmacy information
• Concerns about some semaglutide salt forms being used in products
• Products marketed without appropriate prescriptions or through questionable sources

As of May 31, 2026, the FDA had received 990 adverse-event reports associated with compounded semaglutide. The agency notes that adverse events may be underreported and that an adverse-event report does not necessarily establish that the medication caused the event.

Compounded medications can be legally produced under certain circumstances. The FDA generally advises that compounded drugs should be used when a patient's medical needs cannot be met by an FDA-approved drug. Patients considering a compounded medication should discuss it with their clinician and obtain it from an appropriate licensed pharmacy.

If you're considering compounded semaglutide because of cost, ask your clinician about FDA-approved alternatives and current manufacturer self-pay programs before deciding which option fits your situation.

How to pay less for GLP-1 medications

If you're paying out of pocket, compare the actual cost of treatment rather than focusing only on the lowest advertised price.

Use manufacturer self-pay programs

NovoCare and Lilly's direct-to-consumer programs publish cash prices for eligible patients. Compare those prices with what you would pay through insurance or at your local pharmacy.

Check manufacturer savings programs

If you have commercial insurance, you may qualify for a manufacturer savings program. Eligibility varies, and Medicare and Medicaid beneficiaries are generally excluded from commercial savings-card offers.

Check patient assistance programs

Some manufacturers offer patient assistance programs for people who meet specific eligibility and income requirements. Check the current program terms directly with the manufacturer.

Check Medicaid coverage

Medicaid coverage varies by state and by the indication for which the medication is prescribed. Check your state's Medicaid program and your specific plan rather than assuming coverage is available or excluded.

Compare the full monthly cost

Don't compare medications based only on the advertised starting price. A lower introductory price may apply only to certain doses or a limited number of fills. Look at the price of the dose you'll actually be prescribed, plus any consultation, pharmacy, or insurance costs.

Conclusion

GLP-1 pricing has changed in 2026, particularly for people who qualify for manufacturer self-pay programs. Wegovy tablets start at $149 per month, Foundayo has self-pay pricing starting at $149 for certain doses, and eligible new Wegovy injection patients can currently pay $199 for their first two monthly fills of certain starting doses.

Medicare access has also changed. The Medicare GLP-1 Bridge gives eligible Part D beneficiaries access to certain weight-management GLP-1 medications for $50 per month through December 31, 2027.

Private insurance remains much more variable. Prior authorization, plan exclusions, deductibles, and savings-program eligibility can all change your final cost.

Compounded semaglutide may have a lower advertised price, but it is not FDA-approved, and the FDA has raised concerns about dosing errors, fraudulent products, and quality issues involving some compounded GLP-1 products.

If you're considering a GLP-1, compare the actual price of your prescribed dose rather than the lowest advertised starting price. Ask your clinician and insurer about coverage, manufacturer programs, and the total monthly cost before deciding which option fits your situation.